Citius Pharmaceuticals, Inc. - Common Stock (CTXR)

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a distribution services agreement with Cardinal Health.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Volume analysis on 2025-04-01: stocks with an unusual volume in today's session.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade.

CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024.

Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five months.

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products